drkiransaysdrkiransays Facebook ad: “The conversation around GLP-1s has become extreme dramatic…”
Ran for 4 days, from March 2 to March 6, 2026, the last day Crush saw it.
Run by drkiransays on Instagram. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 3090915614444558
- Platforms
- Relaunches
- 0
Ad text
The conversation around GLP-1s has become extreme dramatic success stories on one end, fear on the other. But medicine lives in nuance. In my latest conversation with @harpersbazaarus , I discuss why microdosing GLP-1s is shifting the narrative from rapid appetite suppression to thoughtful metabolic support. Across India, these medications are increasingly being used without proper screening or structured dose escalation raising safety concerns. While highly effective, GLP-1s require individualised assessment to minimise side effects and preserve their therapeutic benefit. Microdosing allows us to tailor treatment especially for patients sensitive to standard doses or those with lower BMI but persistent insulin resistance. Because patient health must always come before trends or rigid protocols. What are your thoughts on GLP-1 microdosing? Let’s discuss. #drkiransays #drkiransethi #isyaderm #glp1 #glp
